nach oben

Erschienen in:

01.04.2012 | Original Article

Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research

verfasst von: Michelle C. Janelsins, Karen M. Mustian, Oxana G. Palesh, Supriya G. Mohile, Luke J. Peppone, Lisa K. Sprod, Charles E. Heckler, Joseph A. Roscoe, Alan W. Katz, Jacqueline P. Williams, Gary R. Morrow

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Altered levels of cytokines and chemokines may play a role in cancer- and cancer treatment-related cognitive difficulties. In many neurodegenerative diseases, abnormal concentrations of cytokines and chemokines affect neuronal integrity leading to cognitive impairments, but the role of cytokines in chemotherapy-related cognitive difficulties in cancer patients is not well understood. Patients receiving doxorubicin-based (with cyclophosphamide, or cyclophosphamide plus fluorouracil; AC/CAF) chemotherapy or cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy report experiencing cognitive difficulties; because these regimens work by different modes of action, it is possible that they differentially affect cytokine levels.

Methods

This study examined the relationships between cytokine levels (i.e., IL-6, IL-8, and MCP-1) and type of chemotherapy among 54 early-stage breast cancer patients receiving AC/CAF or CMF. Cytokine levels were assessed at two time-points: prior to on-study chemotherapy cycle 2 (cycle 2) and after two consecutive chemotherapy cycles (prior to on-study cycle 4; cycle 4).

Main results

Analyses of variance using cycle 2 levels as a covariate (ANCOVA) were used to determine differences between chemotherapy groups. Levels of IL-6, IL-8, and MCP-1 increased in the AC/CAF group and decreased in the CMF group; the only significant between-group change was in IL-6 (p < 0.05).

Conclusions

These results, although preliminary based on the small sample size, suggest that AC/CAF chemotherapy is more cytokine inducing than CMF. Future studies should confirm these results and explore the distinct inflammatory responses elicited by different chemotherapy regimens when assessing cognitive function in cancer patients.

Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. doi:10.1200/JCO.2009.27.0827 PubMed

Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR (2010) An update on cancer- and chemotherapy-related cognitive difficulties: current status. Sem Onc (in press)

Ahles TA, Saykin AJ (2002) Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3(Suppl 3):S84–S90PubMedCrossRef

Ahles TA, Saykin A (2001) Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19(8):812–820PubMedCrossRef

Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116(1):113–123. doi:10.1007/s10549-008-0114-2 PubMedCrossRef

Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292–2299. doi:10.1002/cncr.20272 PubMedCrossRef

Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356. doi:10.1002/cncr.25098 PubMedCrossRef

Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14(11):1111–1118. doi:10.1007/s00520-006-0037-6 PubMedCrossRef

Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26(7):955–969PubMedCrossRef

10.

Janelsins MC, Roscoe JA, Palesh OG, Mustian KM, Peppone LJ, Heckler CE, Morrow GR (2010) Cognitive difficulties, fatigue, and sleep in cancer patients at pre-chemotherapy, post-chemotherapy, and at three months follow-up. Annals Behav Med 39(S1); abstract

11.

Magaki S, Mueller C, Dickson C, Kirsch W (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42(3):233–240. doi:10.1016/j.exger.2006.09.015 PubMedCrossRef

12.

Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63(4):538–543. doi:10.1001/archneur.63.4.538 PubMedCrossRef

13.

Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E (2006) Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging 27(12):1763–1768. doi:10.1016/j.neurobiolaging.2005.10.007 PubMedCrossRef

14.

Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68(22):1902–1908. doi:10.1212/01.wnl.0000263217.36439.da PubMedCrossRef

15.

Van Den Heuvel C, Thornton E, Vink R (2007) Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res 161:303–316CrossRef

16.

Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7(3):192–201. doi:10.1038/nrc2073 PubMedCrossRef

17.

Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97(11):2919–2925. doi:10.1002/cncr.11382 PubMedCrossRef

18.

Villani F, Busia A, Villani M, Vismara C, Viviani S, Bonfante V (2008) Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori 94(6):803–808PubMed

19.

Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94–102PubMedCrossRef

20.

Mills PJ, Ancoli-Israel S, Parker B, Natarajan L, Hong S, Jain S, Sadler GR, von Kanel R (2008) Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behav Immun 22(1):98–104. doi:10.1016/j.bbi.2007.07.001 PubMedCrossRef

21.

Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi R, Smith B (2005) Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89(3):243–249. doi:10.1007/s10549-004-2175-1 PubMedCrossRef

22.

Yoshitake H (1978) Three characteristic patterns of subjective fatigue symptoms. Ergonomics 21(3):231–233PubMedCrossRef

23.

Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St Clair W, Ratanachaiyavong S, St Clair DK, Butterfield DA (2006) Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 23(1):127–139. doi:10.1016/j.nbd.2006.02.013 PubMedCrossRef

24.

Liedke PE, Reolon GK, Kilpp B, Brunetto AL, Roesler R, Schwartsmann G (2009) Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav 94(2):239–243. doi:10.1016/j.pbb.2009.09.001 PubMedCrossRef

25.

Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60(8):729–735PubMedCrossRef

26.

Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, Villaggio B (2000) Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 27(11):2551–2557PubMed

27.

Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153(9):4159–4168PubMed

Titel: Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research
verfasst von: Michelle C. Janelsins
Karen M. Mustian
Oxana G. Palesh
Supriya G. Mohile
Luke J. Peppone
Lisa K. Sprod
Charles E. Heckler
Joseph A. Roscoe
Alan W. Katz
Jacqueline P. Williams
Gary R. Morrow
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1158-0

Springer Medizin

Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research